Neurological Aspects of Human Glycosylation Disorders

Annual Review of Neuroscience

Volumn 38, Issue , 2015, Pages 105-125

  Freeze, Hudson H ^a   Eklund, Erik A ^b   Ng, Bobby G ^a   Patterson, Marc C ^c  

^a BURNHAM INSTITUTE   (United States)

^b LUND UNIVERSITY   (Sweden)

^c MAYO CLINIC   (United States)

Author keywords

CDG; Congenital disorders; Epilepsy; Glycans; Glycoprotein; Seizures

Indexed keywords

BIOLOGICAL MARKER; GLYCOSAMINOGLYCAN; GLYCOSPHINGOLIPID; GLYCOSYLPHOSPHATIDYLINOSITOL; PHOSPHOMANNOMUTASE; PHOSPHOMANNOMUTASE 2; PROTEOGLYCAN; UNCLASSIFIED DRUG; POLYSACCHARIDE;

ARTICLE; AUTISM; BIOSYNTHESIS; CELL INTERACTION; CELL MIGRATION; CELLS BY BODY ANATOMY; CLINICAL FEATURE; DEGLYCOSYLATION; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; EPILEPSY; EYE MALFORMATION; GLYCOSYLATION; GLYCOSYLATION DISORDER; HUMAN; INTELLECTUAL IMPAIRMENT; INTRACELLULAR SIGNALING; MUSCLE HYPOTONIA; NEUROLOGIC DISEASE; NEUROMUSCULAR JUNCTION DISORDER; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; SEIZURE; ANIMAL; COMPLICATION; CONGENITAL DISORDER OF GLYCOSYLATION; EYE DISEASE; METABOLISM;

ANIMALS; AUTISTIC DISORDER; BIOMARKERS; CONGENITAL DISORDERS OF GLYCOSYLATION; EPILEPSY; EYE DISEASES; GLYCOSAMINOGLYCANS; GLYCOSYLATION; HUMANS; INTELLECTUAL DISABILITY; POLYSACCHARIDES;

EID: 84937434499     PISSN: 0147006X     EISSN: 15454126     Source Type: Book Series    
DOI: 10.1146/annurev-neuro-071714-034019     Document Type: Article

References (150)

1. Abadi RV. 2002. Mechanisms underlying nystagmus. J. R. Soc. Med. 95:231-34
2. Aebi M, Hennet T. 2001. Congenital disorders of glycosylation: genetic model systems lead the way. Trends Cell Biol. 11:136-41
3. Agrawal P, Kurcon T, Pilobello KT, Rakus JF, Koppolu S, et al. 2014. Mapping posttranscriptional regulation of the human glycome uncovers microRNA defining the glycocode. PNAS 111:4338-43
4. Almeida AM, Murakami Y, LaytonDM, Hillmen P, Sellick GS, et al. 2006. Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nat. Med. 12:846-51
5. Amberger J, Bocchini C, Hamosh A. 2011. A new face and new challenges for Online Mendelian Inheritance in Man (OMIM). Hum. Mutat. 32:564-67
6. Aronica E, van Kempen AA, van der HeideM, Poll-The BT, van Slooten HJ, et al. 2005. Congenital disorder of glycosylation type Ia: A clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol. 109:433-42
7. Arranz AM, Perkins KL, Irie F, Lewis DP, Hrabe J, et al. 2014. Hyaluronan deficiency due to Has3 knockout causes altered neuronal activity and seizures via reduction in brain extracellular space. J. Neurosci. 34:6164-76
8. Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, et al. 2008. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 322:967-70
9. Barone R, Fiumara A, Jaeken J. 2014. Congenital disorders of glycosylation with emphasis on cerebellar involvement. Semin. Neurol. 34:357-66
10. Baycin-Hizal D, Gottschalk A, Jacobson E, Mai S, Wolozny D, et al. 2014. Physiologic and pathophysiologic consequences of altered sialylation and glycosylation on ion channel function. Biochem. Biophys. Res. Commun. 453:243-53
11. Belaya K, Finlayson S, Slater CR, Cossins J, LiuWW, et al. 2012. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am. J. Hum. Genet. 91:193-201
12. Belet S, Fieremans N, Yuan X, Van Esch H, Verbeeck J, et al. 2014. Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality. Hum. Mutat. 35:350-55
13. Boccuto L, Aoki K, Flanagan-Steet H, Chen CF, Fan X, et al. 2014. A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. Hum. Mol. Genet. 23:418-33
14. Boukhris A, Schule R, Loureiro JL, Lourenco CM, Mundwiller E, et al. 2013. Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am. J. Hum. Genet. 93:118-23
15. Brockhausen I, Schachter H, Stanley P. 2009. O-GalNAc glycans. See Varki et al. 2009, pp. 115-27
16. Caffaro CE, Luhn K, Bakker H, Vestweber D, Samuelson J, et al. 2008. A single Caenorhabditis elegans Golgi apparatus-type transporter of UDP-glucose, UDP-galactose, UDP-N-acetylglucosamine, and UDP-Nacetylgalactosamine. Biochemistry 47:4337-44
17. CaiM, Yang Y. 2014. Targeted genome editing tools for disease modeling and gene therapy. Curr. Gene Ther. 14:2-9
18. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, et al. 2010. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 142:203-17
19. Carrera IA, Matthijs G, Perez B, Cerdá CP. 2012. DPAGT1-CDG: Report of a patient with fetal hypokinesia phenotype. Am. J. Med. Genet. A 158A:2027-30
20. Chiyonobu T, Inoue N, Morimoto M, Kinoshita T, Murakami Y. 2014. Glycosylphosphatidylinositol (GPI) anchor deficiency caused bymutations in PIGW is associated with West syndrome and hyperphosphatasia with mental retardation syndrome. J. Med. Genet. 51:203-7
21. Cirak S, Foley AR, Herrmann R, Willer T, Yau S, et al. 2013. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain 136:269-81
22. Clement E, Mercuri E, Godfrey C, Smith J, Robb S, et al. 2008. Brain involvement in muscular dystrophies with defective dystroglycan glycosylation. Ann. Neurol. 64:573-82
23. Cline A, Gao N, Flanagan-Steet H, Sharma V, Rosa S, et al. 2012. A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulationmechanism forN-linked glycosylation deficiency. Mol. Biol. Cell 23:4175-87
24. Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS. 2010. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin. Cancer Res. 16:3205-14
25. Cossins J, Belaya K, Hicks D, Salih MA, Finlayson S, et al. 2013. Congenital myasthenic syndromes due to mutations in ALG2 and ALG14. Brain 136:944-56
26. Cremer H, Chazal G, Goridis C, Represa A. 1997. NCAM is essential for axonal growth and fasciculation in the hippocampus. Mol. Cell. Neurosci. 8:323-35
27. Cummings RD, Pierce JM. 2014. The challenge and promise of glycomics. Chem. Biol. 21:1-15
28. de Koning TJ, ToetM, Dorland L, de Vries LS, van den Berg IE, et al. 1998. Recurrent nonimmune hydrops fetalis associated with carbohydrate-deficient glycoprotein syndrome. J. Inherit. Metab. Dis. 21:681-82
29. de la Morena-BarrioME, Hernández-Caselles T, Corral J, Garcá-L ópez R, Martńez-Martńez I, et al. 2013. GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. Orphanet. J. Rare Dis. 8:170
30. Dejgaard K, Theberge JF, Heath-Engel H, Chevet E, Tremblay ML, Thomas DY. 2010. Organization of the Sec61 translocon, studied by high resolution native electrophoresis. J. Proteome Res. 9:1763-71
31. Dennis JW, Nabi IR, Demetriou M. 2009. Metabolism, cell surface organization, and disease. Cell 139:1229-41
32. DityatevA, Dityateva G, Sytnyk V, DellingM, ToniN, et al. 2004. Polysialylated neural cell adhesion molecule promotes remodeling and formation of hippocampal synapses. J. Neurosci. 24:9372-82
33. Ednie AR, Bennett ES. 2012. Modulation of voltage-gated ion channels by sialylation. Compr. Physiol. 2:1269-301
34. Edvardson S, Ashikov A, Jalas C, Sturiale L, Shaag A, et al. 2013a. Mutations in SLC35A3 cause autism spectrum disorder, epilepsy and arthrogryposis. J. Med. Genet. 50:733-39
35. Edvardson S, Baumann AM, Mühlenhoff M, Stephan O, Kuss AW, et al. 2013b. West syndrome caused by ST3Gal-III deficiency. Epilepsia 54:e24-27
36. Ellies LG, SperandioM, Underhill GH, Yousif J, SmithM, et al. 2002. Sialyltransferase specificity in selectin ligand formation. Blood 100:3618-25
37. Engel AG, Ohno K, Sine SM. 1999. Congenital myasthenic syndromes: Recent advances. Arch. Neurol. 56:163-67
38. Engel AG, Shen XM, Selcen D, Sine S. 2012. New horizons for congenital myasthenic syndromes. Ann. N. Y. Acad. Sci. 1275:54-62
39. Enns GM, Shashi V, Bainbridge M, Gambello MJ, Zahir FR, et al. 2014. Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway. Genet. Med. 16:751-58
40. Epi4K Consort., Epilepsy Phenome/Genome Proj. 2013. De novo mutations in epileptic encephalopathies. Nature 501:217-21
41. Esko JD, Kimata K, Lindahl U. 2009. Proteoglycans and sulfated glycosaminoglycans. See Varki et al. 2009, pp. 229-48
42. EuroEPINOMICS-RES Consort., Epilepsy Phenome/Genome Proj., Epi4K Consort. 2014. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am. J. Hum. Genet. 95:360-70
43. Ferguson MAJ, Kinoshita T, Hart GW. 2009. Glycosylphosphatidylinositol anchors. See Varki et al. 2009, pp. 143-61
44. Fragaki K, Ait-El-Mkadem S, Chaussenot A, Gire C, Mengual R, et al. 2013. Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Eur. J. Hum. Genet. 21:528-34
45. FreezeHH. 2013. Understanding human glycosylation disorders: biochemistry leads the charge. J. Biol. Chem. 288:6936-45
46. Freeze HH, Chong JX, Bamshad MJ, Ng BG. 2014. Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am. J. Hum. Genet. 94:161-75
47. Freeze HH, Eklund EA, Ng BG, Patterson MC. 2012. Neurology of inherited glycosylation disorders. Lancet Neurol. 11:453-66
48. Freeze HH, Ng BG. 2011. Golgi glycosylation and human inherited diseases. Cold Spring Harb. Perspect. Biol. 3:A005371
49. Gao XD, Nishikawa A, Dean N. 2004. Physical interactions between the Alg1, Alg2, and Alg11 mannosyltransferases of the endoplasmic reticulum. Glycobiology 14:559-70
50. Gao XD, Tachikawa H, Sato T, Jigami Y, Dean N. 2005. Alg14 recruits Alg13 to the cytoplasmic face of the endoplasmic reticulum to form a novel bipartite UDP-N-acetylglucosamine transferase required for the second step of N-linked glycosylation. J. Biol. Chem. 280:36254-62
51. Garshasbi M, Hadavi V, Habibi H, Kahrizi K, Kariminejad R, et al. 2008. A defect in the TUSC3 gene is associated with autosomal recessive mental retardation. Am. J. Hum. Genet. 82:1158-64
52. Godfrey C, Foley AR, Clement E, Muntoni F. 2011. Dystroglycanopathies: coming into focus. Curr. Opin. Genet. Dev. 21:278-85
53. Hadley B, Maggioni A, Ashikov A, Day CJ, Haselhorst T, Tiralongo J. 2014. Structure and function of nucleotide sugar transporters: current progress. Comput. Struct. Biotechnol. J. 10:23-32
54. Hakomori S. 2004. Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization. Glycoconj. J. 21:125-37
55. Hancock JF. 2004. GPI-anchor synthesis: Ras takes charge. Dev. Cell 6:743-45
56. Harlalka GV, Lehman A, Chioza B, Baple EL, Maroofian R, et al. 2013. Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. Brain 136:3618-24
57. Helander A, Stödberg T, Jaeken J, Matthijs G, Eriksson M, Eggertsen G. 2013. Dolichol kinase deficiency (DOLK-CDG) with a purely neurological presentation caused by a novel mutation. Mol. Genet. Metab. 110:342-44
58. Hildebrandt H, Dityatev A. 2013. Polysialic acid in brain development and synaptic plasticity. Top. Curr. Chem. doi: 10. 1007/128-2013-446
59. HildebrandtH, Muhlenhoff M, Weinhold B, Gerardy-Schahn R. 2007. Dissecting polysialic acid andNCAM functions in brain development. J. Neurochem. 103(Suppl. 1):56-64
60. Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, et al. 2011. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab. 14:811-18
61. Houlden H. 2013. Defective N-linked protein glycosylation pathway in congenital myasthenic syndromes. Brain 136:692-95
62. Hu H, Eggers K, Chen W, Garshasbi M, Motazacker MM, et al. 2011. ST3GAL3 mutations impair the development of higher cognitive functions. Am. J. Hum. Genet. 89:407-14
63. Irie F, Badie-Mahdavi H, Yamaguchi Y. 2012. Autism-like socio-communicative deficits and stereotypies in mice lacking heparan sulfate. PNAS 109:5052-56
64. Jae LT, Raaben M, Riemersma M, van Beusekom E, Blomen VA, et al. 2013. Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 340:479-83
65. Johnson D, Bennett ES. 2008. Gating of the shaker potassium channel is modulated differentially by N-glycosylation and sialic acids. Pflugers Arch. 456:393-405
66. Johnston JJ, Gropman AL, Sapp JC, Teer JK, Martin JM, et al. 2012. The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria. Am. J. Hum. Genet. 90:295-300
67. Kasper BT, Koppolu S, Mahal LK. 2014. Insights into miRNA regulation of the human glycome. Biochem. Biophys. Res. Commun. 445:774-79
68. Kato M, Saitsu H, Murakami Y, Kikuchi K, Watanabe S, et al. 2014. PIGA mutations cause early-onset epileptic encephalopathies and distinctive features. Neurology 82:1587-96
69. Kim S, Westphal V, Srikrishna G, Mehta DP, Peterson S, et al. 2000. Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie). J. Clin. Investig. 105:191-98
70. Kiwamoto T, Brummet ME, Wu F, Motari MG, Smith DF, et al. 2014. Mice deficient in the St3gal3 gene product 2, 3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation. J. Allergy Clin. Immunol. 133:240-47. e1-3
71. Kizuka Y, Kitazume S, Okahara K, Villagra A, Sotomayor EM, Taniguchi N. 2014. Epigenetic regulation of a brain-specific glycosyltransferase N-acetylglucosaminyltransferase-IX (GnT-IX) by specific chromatin modifiers. J. Biol. Chem. 289:11253-61
72. Kjaergaard S, SchwartzM, Skovby F. 2001. Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. Arch. Dis. Child. 85:236-39
73. Kodera H, Nakamura K, Osaka H, Maegaki Y, Haginoya K, et al. 2013. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. Hum. Mutat. 34:1708-14
74. Kong Y, Joshi HJ, Schjoldager KT, Madsen TD, Gerken TA, et al. 2015. Probing polypeptide GalNActransferase isoform substrate specificities by in vitro analysis. Glycobiology 25:55-65
75. KranzC, Sun L, Eklund EA, Krasnewich D, Casey JR, Freeze HH. 2007. CDG-Id in two siblings with partially different phenotypes. Am. J. Med. Genet. A 143A:1414-20
76. Kröcher T, Röckle I, Diederichs U, Weinhold B, Burkhardt H, et al. 2014. A crucial role for polysialic acid in developmental interneuron migration and the establishment of interneuron densities in the mouse prefrontal cortex. Development 141:3022-32
77. Kuki I, Takahashi Y, Okazaki S, Kawawaki H, Ehara E, et al. 2013. Vitamin B6-responsive epilepsy due to inherited GPI deficiency. Neurology 81:1467-69
78. Lander AD. 2007. Morpheus unbound: Reimagining the morphogen gradient. Cell 128:245-56
79. Lefeber DJ, Schönberger J, Morava E, Guillard M, Huyben KM, et al. 2009. Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am. J. Hum. Genet. 85:76-86
80. Levenson D. 2014. Mutations in NGLY1 gene linked with new genetic disorder: Parents' reports of children's symptoms help facilitate the discovery. Am. J. Med. Genet. A 164:viii-ix
81. Li H, Chavan M, Schindelin H, Lennarz WJ, Li H. 2008. Structure of the oligosaccharyl transferase complex at 12 A resolution. Structure 16:432-40
82. Lommel M, Winterhalter PR, Willer T, Dahlhoff M, Schneider MR, et al. 2013. Protein O-mannosylation is crucial for E-cadherin-mediated cell adhesion. PNAS 110:21024-29
83. Losfeld ME, Ng BG, Kircher M, Buckingham KJ, Turner EH, et al. 2014. A new congenital disorder of glycosylation caused by a mutation in SSR4, the signal sequence receptor 4 protein of the TRAP complex. Hum. Mol. Genet. 23:1602-5
84. Lu J, Takahashi T, Ohoka A, Nakajima K, Hashimoto R, et al. 2012. Alg14 organizes the formation of a multiglycosyltransferase complex involved in initiation of lipid-linked oligosaccharide biosynthesis. Glycobiology 22:504-16
85. Martin HC, Kim GE, Pagnamenta AT, Murakami Y, Carvill GL, et al. 2014. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum. Mol. Genet. 23:3200-11
86. Martin PT. 2005. The dystroglycanopathies: the new disorders of O-linked glycosylation. Semin. Pediatr. Neurol. 12:152-58
87. Maszczak-Seneczko D, Sosicka P, Olczak T, Jakimowicz P, Majkowski M, Olczak M. 2013. UDP-Nacetylglucosamine transporter (SLC35A3) regulates biosynthesis of highly branched N-glycans and keratan sulfate. J. Biol. Chem. 288:21850-60
88. Maydan G, Noyman I, Har-Zahav A, Neriah ZB, Pasmanik-Chor M, et al. 2011. Multiple congenital anomalies-hypotonia-seizures syndrome is caused by a mutation in PIGN. J. Med. Genet. 48:383-89
89. Michaud JL, Lachance M, Hamdan FF, Carmant L, Lortie A, et al. 2014. The genetic landscape of infantile spasms. Hum. Mol. Genet. 23:4846-58
90. Might M, Wilsey M. 2014. The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated. Genet. Med. 16:736-37
91. Mohorko E, Owen RL, Malojcíc G, Brozzo MS, Aebi M, Glockshuber R. 2014. Structural basis of substrate specificity of human oligosaccharyl transferase subunit N33/Tusc3 and its role in regulating protein N-glycosylation. Structure 22:590-601
92. Molinari F, Foulquier F, Tarpey PS, Morelle W, Boissel S, et al. 2008. Oligosaccharyltransferase-subunit mutations in nonsyndromic mental retardation. Am. J. Hum. Genet. 82:1150-57
93. Morava E, Vodopiutz J, Lefeber DJ, Janecke AR, Schmidt WM, et al. 2012. Defining the phenotype in congenital disorder of glycosylation due to ALG1 mutations. Pediatrics 130:e1034-39
94. Morava E, Wevers RA, Cantagrel V, Hoefsloot LH, Al-Gazali L, et al. 2010. A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism. Brain 133:3210-20
95. Muppidi S, Wolfe GI, Barohn RJ. 2012. Disease of the neuromuscular junction. In Swaiman's Pediatric Neurology, ed. KF Swaiman, S Ashwal, DM Ferriero, N Schor, pp. 1549-69. New York: Elsevier
96. Ng BG, Buckingham KJ, Raymond K, Kircher M, Turner EH, et al. 2013. Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation. Am. J. Hum. Genet. 92:632-36
97. Ng BG, Freeze HH. 2015. Human genetic disorders involving glycosylphosphatidylinositol (GPI) anchors and glycosphingolipids (GSL). J. Inherit. Metab. Dis. 38:171-78
98. NowyckyMC, WuG, Ledeen RW. 2014. Glycobiology of ion transport in the nervous system. Adv. Neurobiol. 9:321-42
99. O'Connell TM, King D, Dixit CK, O'Connor B, Walls D, Ducrée J. 2014. Sequential glycan profiling at single cell level with the microfluidic lab-in-a-trench platform: A new era in experimental cell biology. Lab Chip 14:3629-39
100. Orr SL, Le D, Long JM, Sobieszczuk P, Ma B, et al. 2013. A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins. Glycobiology 23:363-80
101. Parker CJ. 2012. Paroxysmal nocturnal hemoglobinuria. Curr. Opin. Hematol. 19:141-48
102. ParkinsonW, DearML, Rushton E, Broadie K. 2013. N-glycosylation requirements in neuromuscular synaptogenesis. Development 140:4970-81
103. Pedersen ME, Snieckute G, Kagias K, Nehammer C, Multhaupt HA, et al. 2013. An epidermal microRNA regulates neuronal migration through control of the cellular glycosylation state. Science 341:1404-408
104. Pernet V, Schwab ME. 2012. The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res. 349:97-104
105. Praissman JL, Wells L. 2014. Mammalian O-mannosylation pathway: glycan structures, enzymes, and protein substrates. Biochemistry 53:3066-78
106. Pribiag H, Peng H, ShahWA, Stellwagen D, Carbonetto S. 2014. Dystroglycan mediates homeostatic synaptic plasticity at GABAergic synapses. PNAS 111:6810-15
107. Rosen CL, LisantiMP, Salzer JL. 1992. Expression of unique sets of GPI-linked proteins by different primary neurons in vitro. J. Cell Biol. 117:617-27
108. Schenk B, Imbach T, Frank CG, Grubenmann CE, Raymond GV, et al. 2001. MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. J. Clin. Investig. 108:1687-95
109. Schjoldager KT, Clausen H. 2012. Site-specific protein O-glycosylation modulates proprotein processing deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim. Biophys. Acta 1820:2079-94
110. Schjoldager KT, Vakhrushev SY, Kong Y, Steentoft C, Nudelman AS, et al. 2012. Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells. PNAS 109:9893-98
111. Schnaar RL, Gerardy-Schahn R, Hildebrandt H. 2014. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol. Rev. 94:461-518
112. Schnaar RL, Suzuki A, Stanley P. 2009. Glycosphingolipids. See Varki et al. 2009, pp. 129-41
113. Senderek J, Müller JS, Dusl M, Strom TM, Guergueltcheva V, et al. 2011. Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am. J. Hum. Genet. 88:162-72
114. Senkov O, Tikhobrazova O, Dityatev A. 2012. PSA-NCAM: synaptic functions mediated by its interactions with proteoglycans and glutamate receptors. Int. J. Biochem. Cell Biol. 44:591-95
115. Sharma V, Ichikawa M, Freeze HH. 2014. Mannose metabolism: more than meets the eye. Biochem. Biophys. Res. Commun. 453:220-28
116. Shi Z, Ruvkun G. 2012. Themevalonate pathway regulates microRNA activity in Caenorhabditis elegans. PNAS 109:4568-73
117. Shibatani T, David LL, McCormack AL, Frueh K, Skach WR. 2005. Proteomic analysis of mammalian oligosaccharyltransferase reveals multiple subcomplexes that contain Sec61, TRAP, and two potential new subunits. Biochemistry 44:5982-92
118. Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, et al. 2004. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat. Genet. 36:1225-29
119. SmithDF, Cummings RD. 2014. Investigating virus-glycan interactions using glycan microarrays. Curr. Opin. Virol. 7C:79-87
120. Spiro RG. 2002. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12:43R-56
121. Stalnaker SH, Aoki K, Lim JM, Porterfield M, Liu M, et al. 2011. Glycomic analyses of mouse models of congenital muscular dystrophy. J. Biol. Chem. 286:21180-90
122. Stanley P, Schachter H, Taniguchi N. 2009. N-glycans. See Varki et al. 2009, pp. 101-14
123. Steentoft C, Bennett EP, Schjoldager KT, Vakhrushev SY, Wandall HH, ClausenH. 2014. Precision genome editing: A small revolution for glycobiology. Glycobiology 24:663-80
124. Sun L, Zhao Y, Zhou K, FreezeHH, Zhang YW, Xu H. 2013. Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation. Mol. Brain 6:52
125. Swoboda KJ, Margraf RL, Carey JC, Zhou H, Newcomb TM, et al. 2014. A novel germline PIGA mutation in Ferro-Cerebro-Cutaneous syndrome: A neurodegenerative X-linked epileptic encephalopathy with systemic iron-overload. Am. J. Med. Genet. A 164A:17-28
126. Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, et al. 1996. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. PNAS 93:10662-67
127. Tegtmeyer LC, Rust S, van Scherpenzeel M, Ng BG, Losfeld ME, et al. 2014. Multiple phenotypes in phosphoglucomutase 1 deficiency. N. Engl. J. Med. 370:533-42
128. Tennant KA. 2014. Thinking outside the brain: structural plasticity in the spinal cord promotes recovery from cortical stroke. Exp. Neurol. 254:195-99
129. Tettamanti G, Bonali F, Marchesini S, Zambotti V. 1973. A new procedure for the extraction, purification and fractionation of brain gangliosides. Biochim. Biophys. Acta 296:160-70
130. Thompson MD, Killoran A, Percy ME, Nezarati M, Cole DE, Hwang PA. 2006. Hyperphosphatasia with neurologic deficit: A pyridoxine-responsive seizure disorder Pediatr. Neurol. 34:303-7
131. van Bokhoven H. 2011. Genetic and epigenetic networks in intellectual disabilities. Annu. Rev. Genet. 45:81-104
132. van der Crabben SN, Harakalova M, Brilstra EH, van Berkestijn FM, Hofstede FC, et al. 2014. Expanding the spectrum of phenotypes associated with germline PIGA mutations: A child with developmental delay, accelerated linear growth, facial dysmorphisms, elevated alkaline phosphatase, and progressive CNS abnormalities. Am. J. Med. Genet. A 164A:29-35
133. Varki A. 1993. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3:97-130
134. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, et al., eds. 2009. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press
135. Varki A, Sharon N. 2009. Historical background and overview. See Varki et al. 2009, pp. 1-22
136. Verrotti A, Spalice A, Ursitti F, Papetti L, Mariani R, et al. 2010. New trends in neuronal migration disorders. Eur. J. Paediatr. Neurol. 14:1-12
137. Vester-Christensen MB, Halim A, Joshi HJ, Steentoft C, Bennett EP, et al. 2013. Mining the O-mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. PNAS 110:21018-23
138. Vuillaumier-Barrot S, Bouchet-Séraphin C, Chelbi M, Devisme L, Quentin S, et al. 2012. Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am. J. Hum. Genet. 91:1135-43
139. Wakil SM, Monies DM, Ramzan K, Hagos S, Bastaki L, et al. 2014. Novel B4GALNT1 mutations in a complicated form of hereditary spastic paraplegia. Clin. Genet. 86:500-1
140. Wang Y, Schachter H, Marth JD. 2002. Mice with a homozygous deletion of the Mgat2 gene encoding UDP-N-acetylglucosamine:Alpha-6-D-mannoside beta1, 2-N-acetylglucosaminyltransferase II: A model for congenital disorder of glycosylation type IIa. Biochim. Biophys. Acta 1573:301-11
141. Willett R, UngarD, Lupashin V. 2013. TheGolgi puppetmaster:COG complex at center stage ofmembrane trafficking interactions. Histochem. Cell Biol. 140:271-83
142. Wills ZP, Mandel-Brehm C, Mardinly AR, McCord AE, Giger RJ, Greenberg ME. 2012. The nogo receptor family restricts synapse number in the developing hippocampus. Neuron 73:466-81
143. Wu X, Rush JS, Karaoglu D, Krasnewich D, Lubinsky MS, et al. 2003. Deficiency of UDP-GlcNAc:Dolichol phosphate N-acetylglucosamine-1 phosphate transferase (DPAGT1) causes a novel congenital disorder of glycosylation type Ij. Hum. Mutat. 22:144-50
144. Yoshida-Moriguchi T, Yu L, Stalnaker SH, Davis S, Kunz S, et al. 2010. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 327:88-92
145. Zelinger L, Banin E, Obolensky A, Mizrahi-Meissonnier L, Beryozkin A, et al. 2011. A missense mutation in DHDDS, encoding dehydrodolichyl diphosphate synthase, is associated with autosomal-recessive retinitis pigmentosa in Ashkenazi Jews. Am. J. Hum. Genet. 88:207-15
146. Zhang YT, Lander AD, Nie Q. 2007. Computational analysis of BMP gradients in dorsal-ventral patterning of the zebrafish embryo. J. Theor. Biol. 248:579-89
147. Zhou H, Clapham DE. 2009. Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. PNAS 106:15750-55
148. Zielinska DF, Gnad F, Wisniewski JR, Mann M. 2010. Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 141:897-907
149. Zoltowska K, Webster R, Finlayson S, Maxwell S, Cossins J, et al. 2013. Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR. Hum. Mol. Genet. 22:2905-13
150. Züchner S, Dallman J, Wen R, Beecham G, Naj A, et al. 2011. Whole-exome sequencing links a variant in DHDDS to retinitis pigmentosa. Am. J. Hum. Genet. 88:201-6